GlassScriptPhysician profile
Martin Taylor
NPI 1578535092
$2,185.79
in general payments reported to CMS, 2019-2025
33 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.76 · 2020: $88.54 · 2021: $77.15 · 2022: $128 · 2023: $771 · 2024: $620 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $382.75 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $303.52 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $272.15 | 2023-2025 | Vraylar, Ubrelvy, Viberzi |
| Otsuka America Pharmaceutical, INC. | $168.18 | 2022-2025 | Rexulti, Abilify Maintena |
| Mylan Specialty L.P. | $158.55 | 2022-2024 | Yupelri |
| Halozyme INC | $143.93 | 2023 | |
| Lilly USA, LLC | $68.19 | 2020-2024 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $50.00 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $46.63 | 2023-2024 | Ingrezza |
| Pfizer INC. | $45.02 | 2024 | |
| Dexcom, INC. | $37.07 | 2021-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.88 | 2025 | Caplyta |
| Exact Sciences Corporation | $35.08 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $34.12 | 2022-2023 | Seglentis |
| Antares Pharma, INC. | $32.64 | 2024-2025 | Xyosted |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.55 | 2023-2024 | Repatha, Otezla |
| Shield Therapeutics INC | $31.66 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.05 | 2023-2024 | Xifaxan |
| Tactile Systems Technology INC | $23.95 | 2024 | Entre Plus, Flexitouch Plus |
| Daiichi Sankyo INC. | $23.08 | 2021 | |
| Abbott Laboratories | $22.95 | 2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $22.76 | 2024 | Rivfloza |
| Astellas Pharma US INC | $21.71 | 2024 | Veozah |
| Organon LLC | $21.69 | 2024 | |
| Verona Pharma, INC. | $19.28 | 2025 | Ohtuvayre |
| Galderma Laboratories, L.P. | $18.27 | 2024 | |
| Tolmar, INC. | $17.93 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.44 | 2023 | Quviviq |
| Seqirus USA INC | $15.42 | 2023 | Fluad Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.77 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $13.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.01 | 2021 | |
| Allergan, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.